New Dual Agonist Shows Positive Results for Type 1 Diabetes and Obesity

A Phase 2 clinical trial presented promising findings for acmopatide, a dual GLP-1/GIP receptor agonist. The drug demonstrated improvements in glycemic control, weight reduction, and blood pressure for adults managing type 1 diabetes alongside obesity. These results suggest a potential new therapeutic avenue for this complex health challenge.